Is Guardant Health Stock a Good Investment?
Guardant Health Investment Advice | GH |
- Examine Guardant Health's financial health by looking at its balance sheet, income statement, and cash flow statement. Analyze key financial ratios, such as Price-to-Earnings (P/E), Price-to-Sales (P/S), and Price-to-Book (P/B), to determine whether the stock is fairly valued or over/undervalued.
- Research Guardant Health's leadership team and their track record. Good management can help Guardant Health navigate difficult times and make strategic decisions that benefit shareholders and increases its net worth.
- Consider the overall health of the Health Care Providers & Services space and any emerging trends that could impact Guardant Health's business and its evolving consumer preferences.
- Compare Guardant Health's performance and market position to its competitors. Analyze how Guardant Health is positioned in terms of product offerings, innovation, and market share.
- Check if Guardant Health pays a dividend and its dividend yield and payout ratio.
- Review what financial analysts are saying about Guardant Health's stock and their price targets. However, remember that analysts' opinions can vary, and their predictions may not always be accurate.
It's important to note that investing in Guardant Health stock, carries risks, and you should carefully consider your investment goals and risk tolerance before making any investment decisions. Also, remember that it's important for investors to have a long-term perspective and a well-diversified portfolio to manage the impact of stock market volatility on their investments. Below is a detailed guide on how to decide if Guardant Health is a good investment.
Sell | Buy |
Strong Hold
Market Performance | Good | Details | |
Volatility | Not too volatile | Details | |
Hype Condition | Stale | Details | |
Current Valuation | Overvalued | Details | |
Odds Of Distress | Below Average | Details | |
Economic Sensitivity | Hyperactively responds to market trends | Details | |
Investor Sentiment | Alarmed | Details | |
Analyst Consensus | Strong Buy | Details | |
Financial Leverage | Not Rated | Details | |
Reporting Quality (M-Score) | Unavailable | Details |
Examine Guardant Health Stock
Researching Guardant Health's stock involves analyzing various aspects of the company and its industry to make an informed investment decision. The key areas to focus on are fundamentals, business model and competitive advantage. It is also important to analyze trends in revenue, net income, and cash flow, as well as key financial ratios, such as price-to-earnings (P/E), price-to-sales (P/S), and debt-to-equity (D/E). About 99.0% of the company shares are owned by institutional investors. The company recorded a loss per share of 3.56. Guardant Health had not issued any dividends in recent years.
To determine if Guardant Health is a good investment, evaluating the company's potential for future growth is also very important. This may include expanding into new markets, launching new products or services, or improving operational efficiency. Companies with strong growth prospects can be more attractive investments. This aspect of the research should be conducted in the context of the overall market and industry in which the company operates and should include an analysis of growth potential, competitive landscape, and any regulatory or economic factors that could impact the business. Some of the essential points regarding Guardant Health's research are outlined below:
| Guardant Health is way too risky over 90 days horizon | |
| Guardant Health appears to be risky and price may revert if volatility continues | |
| The company generated the yearly revenue of 739.02 M. Annual Net Loss to common stockholders was (436.37 M) with gross profit of 449.22 M. | |
| Guardant Health reports about 853.69 M in cash with (239.86 M) of positive cash flow from operations. This results in cash-per-share (CPS) ratio of 8.35. | |
| Over 99.0% of the company shares are owned by institutional investors | |
| Latest headline from MacroaxisInsider: Disposition of 116 shares by Tariq Musa of Guardant Health at 43.7 subject to Rule 16b-3 |
Guardant Health uses earnings reports to provide investors with an update of all three financial statements, including the income statement, the balance sheet, and the cash flow statement. Therefore, it is also crucial when considering investing in Guardant Health. Every quarterly earnings report provides investors with an overview of sales, expenses, and net income for the most recent period. It also may provide a comparison to Guardant Health's previous reporting period. The quarterly earnings reports are usually disseminated to the public via Form 10-Q, which is a legal document filed with the Securities and Exchange Commission every quarter.
| 22nd of February 2024 Upcoming Quarterly Report | View | |
| 14th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 22nd of February 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Earnings surprises can significantly impact Guardant Health's stock price both in the short term and over time. Negative earnings surprises usually result in a price decline. However, it has been seen that positive earnings surprises lead to an immediate rise in a stock's price and a gradual increase over time. This is why we often hear news about some companies beating earning projections. Financial analysts spend a large amount of time predicting earnings per share (EPS) along with other important future indicators. Many analysts use forecasting models, management guidance, and additional fundamental information to derive an EPS estimate. Below are the table of largest EPS Surprises Guardant Health's investors have experienced.
| Reported | Fiscal Date | Estimated EPS | Reported EPS | Surprise | |||
|---|---|---|---|---|---|---|---|
2020-02-24 | 2019-12-31 | -0.31 | -0.27 | 0.04 | 12 | ||
2019-03-12 | 2018-12-31 | -0.35 | -0.3 | 0.05 | 14 | ||
2019-05-09 | 2019-03-31 | -0.37 | -0.3 | 0.07 | 18 | ||
2024-05-09 | 2024-03-31 | -0.85 | -0.94 | -0.09 | 10 | ||
2024-08-07 | 2024-06-30 | -0.74 | -0.84 | -0.1 | 13 | ||
2020-05-07 | 2020-03-31 | -0.39 | -0.29 | 0.1 | 25 | ||
2021-08-05 | 2021-06-30 | -0.85 | -0.96 | -0.11 | 12 | ||
2025-02-20 | 2024-12-31 | -0.5038 | -0.62 | -0.1162 | 23 |
Know Guardant Health's Top Institutional Investors
Have you ever been surprised when a price of an equity instrument such as Guardant Health is soaring high without any particular reason? This is usually happening because many institutional investors are aggressively trading Guardant Health backward and forwards among themselves. Guardant Health's institutional investor refers to the entity that pools money to purchase Guardant Health's securities or originate loans. Institutional investors include commercial and private banks, credit unions, insurance companies, pension funds, hedge funds, endowments, and mutual funds. Operating companies that invest excess capital in these types of assets may also be included in the term and may influence corporate governance by exercising voting rights in their investments.
| Shares | Ubs Asset Mgmt Americas Inc | 2024-12-31 | 2.6 M | Two Sigma Advisers, Llc | 2024-12-31 | 2.3 M | Fuller & Thaler Asset Management Inc | 2024-12-31 | 2 M | Fidelity International Ltd | 2024-12-31 | 1.9 M | Two Sigma Investments Llc | 2024-12-31 | 1.9 M | Ubs Group Ag | 2024-12-31 | 1.8 M | Temasek Holdings Ltd. | 2024-12-31 | 1.6 M | Goldman Sachs Group Inc | 2024-12-31 | 1.5 M | Citadel Advisors Llc | 2024-12-31 | 1.5 M | Vanguard Group Inc | 2024-12-31 | 12.1 M | Blackrock Inc | 2024-12-31 | 11.7 M |
Guardant Health's market capitalization trends
The company currently falls under 'Mid-Cap' category with a market capitalization of 5.69 B.Market Cap |
|
Guardant Health's profitablity analysis
| Last Reported | Projected for Next Year | ||
| Return On Tangible Assets | (0.30) | (0.31) | |
| Return On Capital Employed | (0.35) | (0.37) | |
| Return On Assets | (0.29) | (0.31) | |
| Return On Equity | 3.12 | 3.28 |
Determining Guardant Health's profitability involves analyzing its financial statements and using various financial metrics to determine if Guardant Health is a good buy. For example, gross profit margin measures Guardant Health's profitability after accounting for the cost of goods sold, while net profit margin measures profitability after accounting for all expenses. Other important metrics include return on assets, return on equity, and free cash flow. By reviewing multiple sources and metrics, you can gain a complete picture of Guardant Health's profitability and make more informed investment decisions.
Guardant Health's Earnings Breakdown by Geography
Evaluate Guardant Health's management efficiency
Guardant Health has Return on Asset (ROA) of (0.1695) % which means that for every 100 dollars spent on asset, it generated a loss of $0.1695. This is way below average. Likewise, it shows a return on total equity (ROE) of (45.8447) %, which implies that it produced no returns to current stockholders. Guardant Health's management efficiency ratios could be used to measure how well Guardant Health manages its routine affairs as well as how well it operates its assets and liabilities. The Guardant Health's current Return On Equity is estimated to increase to 3.28, while Return On Tangible Assets are projected to decrease to (0.31). As of now, Guardant Health's Intangibles To Total Assets are decreasing as compared to previous years. The Guardant Health's current Debt To Assets is estimated to increase to 0.94, while Total Assets are projected to decrease to under 1.4 B.| Last Reported | Projected for Next Year | ||
| Book Value Per Share | (1.14) | (1.08) | |
| Tangible Book Value Per Share | (1.22) | (1.16) | |
| Enterprise Value Over EBITDA | (11.69) | (12.27) | |
| Price Book Value Ratio | (26.85) | (25.51) | |
| Enterprise Value Multiple | (11.69) | (12.27) | |
| Price Fair Value | (26.85) | (25.51) |
Examining the leadership quality of Guardant Health offers valuable insights into its operational efficiency and financial health. This analysis assists investors in making informed decisions regarding the stock.
Beta 1.503 |
Basic technical analysis of Guardant Stock
As of the 23rd of March, Guardant Health retains the market risk adjusted performance of 0.2976, and Risk Adjusted Performance of 0.1036. Guardant Health technical analysis makes it possible for you to employ historical prices and volume momentum with the intention to determine a pattern that calculates the direction of the firm's future prices.Guardant Health's insider trading activities
Some recent studies suggest that insider trading raises the cost of capital for securities issuers and decreases overall economic growth. Trading by specific Guardant Health insiders, such as employees or executives, is commonly permitted as long as it does not rely on Guardant Health's material information that is not in the public domain. Local jurisdictions usually require such trading to be reported in order to monitor insider transactions. In many U.S. states, trading conducted by corporate officers, key employees, directors, or significant shareholders must be reported to the regulator or publicly disclosed, usually within a few business days of the trade. In these cases Guardant Health insiders are required to file a Form 4 with the U.S. Securities and Exchange Commission (SEC) when buying or selling shares of their own companies.
Guardant Health's Outstanding Corporate Bonds
Guardant Health issues bonds to finance its operations. Corporate bonds make up one of the largest components of the U.S. bond market, which is considered the world's largest securities market. Guardant Health uses the proceeds from bond sales for a wide variety of purposes, including financing ongoing mergers and acquisitions, buying new equipment, investing in research and development, buying back their own stock, paying dividends to shareholders, and even refinancing existing debt. Most Guardant bonds can be classified according to their maturity, which is the date when Guardant Health has to pay back the principal to investors. Maturities can be short-term, medium-term, or long-term (more than ten years). Longer-term bonds usually offer higher interest rates but may entail additional risks.
| US40139LAG86 Corp BondUS40139LAG86 | View | |
| GUARDN 3246 29 MAR 27 Corp BondUS40139LBF94 | View | |
| US401378AC83 Corp BondUS401378AC83 | View | |
| US401378AB01 Corp BondUS401378AB01 | View | |
| US40139LBC63 Corp BondUS40139LBC63 | View | |
| GUARDN 125 13 MAY 26 Corp BondUS40139LBD47 | View | |
| AerCap Global Aviation Corp BondUS00773HAA59 | View |
Understand Guardant Health's technical and predictive indicators
Using predictive indicators to make investment decisions involves analyzing Guardant Health's various financial and market-based factors to help forecast future trends and identify investment opportunities. Select the indicators that are most relevant to your investment strategy. Each indicator has its own strengths and weaknesses, so it's essential to combine multiple indicators to get a more comprehensive view of the market and reduce the risk of making poor decisions based on limited data.
| Risk Adjusted Performance | 0.1036 | |||
| Market Risk Adjusted Performance | 0.2976 | |||
| Mean Deviation | 3.41 | |||
| Semi Deviation | 3.6 | |||
| Downside Deviation | 4.11 | |||
| Coefficient Of Variation | 929.9 | |||
| Standard Deviation | 5.12 | |||
| Variance | 26.26 | |||
| Information Ratio | 0.1187 | |||
| Jensen Alpha | 0.6678 | |||
| Total Risk Alpha | 0.9302 | |||
| Sortino Ratio | 0.1481 | |||
| Treynor Ratio | 0.2876 | |||
| Maximum Drawdown | 32.66 | |||
| Value At Risk | (5.93) | |||
| Potential Upside | 6.28 | |||
| Downside Variance | 16.88 | |||
| Semi Variance | 12.94 | |||
| Expected Short fall | (3.62) | |||
| Skewness | 1.77 | |||
| Kurtosis | 6.88 |
| Risk Adjusted Performance | 0.1036 | |||
| Market Risk Adjusted Performance | 0.2976 | |||
| Mean Deviation | 3.41 | |||
| Semi Deviation | 3.6 | |||
| Downside Deviation | 4.11 | |||
| Coefficient Of Variation | 929.9 | |||
| Standard Deviation | 5.12 | |||
| Variance | 26.26 | |||
| Information Ratio | 0.1187 | |||
| Jensen Alpha | 0.6678 | |||
| Total Risk Alpha | 0.9302 | |||
| Sortino Ratio | 0.1481 | |||
| Treynor Ratio | 0.2876 | |||
| Maximum Drawdown | 32.66 | |||
| Value At Risk | (5.93) | |||
| Potential Upside | 6.28 | |||
| Downside Variance | 16.88 | |||
| Semi Variance | 12.94 | |||
| Expected Short fall | (3.62) | |||
| Skewness | 1.77 | |||
| Kurtosis | 6.88 |
Consider Guardant Health's intraday indicators
Guardant Health intraday indicators are useful technical analysis tools used by many experienced traders. Just like the conventional technical analysis, daily indicators help intraday investors to analyze the price movement with the timing of Guardant Health stock daily movement. By combining multiple daily indicators into a single trading strategy, you can limit your risk while still earning strong returns on your managed positions.
Guardant Health Corporate Filings
F4 | 20th of March 2025 The report filed by a party regarding the acquisition or disposition of a company's common stock, as well as derivative securities such as options, warrants, and convertible securities | ViewVerify |
| 24th of February 2025 Other Reports | ViewVerify | |
8K | 20th of February 2025 Report filed with the SEC to announce major events that shareholders should know about | ViewVerify |
| 13th of February 2025 Other Reports | ViewVerify |
Guardant Stock media impact
Far too much social signal, news, headlines, and media speculation about Guardant Health that are available to investors today. That information is available publicly through Guardant media outlets and privately through word of mouth or via Guardant internal channels. However, regardless of the origin, that massive amount of Guardant data is challenging to quantify into actionable patterns, especially for investors that are not very sophisticated with ever-evolving tools and techniques used in the investment management field.
A primary focus of Guardant Health news analysis is to determine if its current price reflects all relevant headlines and social signals impacting the current market conditions. A news analyst typically looks at the history of Guardant Health relative headlines and hype rather than examining external drivers such as technical or fundamental data. It is believed that price action tends to repeat itself due to investors' collective, patterned thinking related to Guardant Health's headlines and news coverage data. This data is often completely overlooked or insufficiently analyzed for actionable insights to drive Guardant Health alpha.
Guardant Health Sentiment by Major News Outlets
Investor sentiment, mood or attitude towards Guardant Health can have a significant impact on its stock price or the market as a whole. This sentiment can be positive or negative, and various factors, such as economic indicators, news events, or market trends, can influence it. When investor sentiment is positive, investors are more likely to buy stocks, increasing demand and increasing the stock price. Positive investor sentiment can be driven by good news about the company or the broader market, such as solid earnings reports or positive economic data.
Note that negative investor sentiment can cause investors to sell stocks, leading to a decrease in demand and a drop in the stock price. Negative sentiment can be driven by factors such as poor earnings reports, negative news about the company or industry, or broader economic concerns. It's important to note that investor sentiment is just one of many factors that can affect stock prices. Other factors, such as company performance, industry trends, and global economic conditions, can also play a significant role in determining the value of a stock.
Guardant Health Historical Investor Sentiment
Investor biases related to Guardant Health's public news can be used to forecast risks associated with an investment in Guardant. The trend in average sentiment can be used to explain how an investor holding Guardant can time the market purely based on public headlines and social activities around Guardant Health. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Guardant Health's market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Guardant Health and other traded tickers. The bigger the bubble, the more accurate the estimated score. Higher bars for a given day show more participation in the average Guardant Health news discussions. The higher the estimate score, the more favorable the investor's outlook on Guardant Health.
Guardant Health Corporate Management
| Jennifer Higgins | Senior Affairs | Profile | |
| Stephen Murphy | Senior Marketing | Profile | |
| John Saia | Chief Secretary | Profile | |
| Christopher Freeman | Chief Officer | Profile | |
| John JD | Chief Secretary | Profile | |
| Zarak Khurshid | Vice Relations | Profile |
Check out Risk vs Return Analysis to better understand how to build diversified portfolios, which includes a position in Guardant Health. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in rate. For more detail on how to invest in Guardant Stock please use our How to Invest in Guardant Health guide.You can also try the Idea Optimizer module to use advanced portfolio builder with pre-computed micro ideas to build optimal portfolio .
Is Health Care Providers & Services space expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Guardant Health. If investors know Guardant will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Guardant Health listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Earnings Share (3.56) | Revenue Per Share | Quarterly Revenue Growth 0.302 | Return On Assets | Return On Equity |
The market value of Guardant Health is measured differently than its book value, which is the value of Guardant that is recorded on the company's balance sheet. Investors also form their own opinion of Guardant Health's value that differs from its market value or its book value, called intrinsic value, which is Guardant Health's true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Guardant Health's market value can be influenced by many factors that don't directly affect Guardant Health's underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
In summary, please note that there is a difference between Guardant Health's value and its price, as these two are different measures arrived at by various means. Investors typically determine if Guardant Health is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Guardant Health's price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.